The approval relies on positive data from the POTOMAC Phase III trial.

The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer ...

AstraZeneca announces CARES phase III clinical programme fails to meet primary endpoint in overall light chain amyloidosis population: Cambridge, UK Monday, June 1, 2026, 12:00 Hr ...

AstraZeneca PLC (NYSE:AZN) is one of the best stocks to buy now for long term growth. AstraZeneca PLC (NYSE:AZN) reported on ...

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to a 62% improvement in survival among a prespecified subgroup of ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

The U.K. drugmaker recently direct-listed its shares in the U.S., betting on a new-drug pipeline to achieve its revenue target by 2030.